



Pharma Finance 2007

ROMA - ITALY - MAY 10-11

5TH ANNUAL PARTNERING CONFERENCE

Market Data (AS OF MAY 1, 2007)



Symbol	NVD
Exchange	AMEX
Current Price	\$1.25
Shares Outstanding	59.4M
Market Capital	\$74.2M
52wk RANGE	\$1.06-\$2.00
Average Volume	205,369
YTD % Change	-23%

COMPANY FACT SHEET



NovaDel Pharma
25 Minneakoning Road
Flemington, NJ 08822
(908) 806-7624

www.novadel.com



Dr. Jan H. Egberts
President and CEO

FINANCIAL HIGHLIGHTS (YEAR ENDING DEC 31ST, 2006)

Net Revenue:	4.96M	Earnings per Share:	(0.18)
Net Income:	(9.13M)	Weighted Average:	49.5M

CONFERENCE OBJECTIVES

Partnering and Licensing opportunities.

RECENT DEVELOPMENTS

March 23, 2007

NovaDel's European Formulation of Ondansetron Targeted for U.S. Zensana

February 26, 2007

NovaDel Pharma Announces the Completion of Its Executive Team

February 2, 2007

NovaDel Pharma Appoints Mark J. Baric to its Board of Directors

PRODUCT AND PRODUCT CANDIDATE PIPELINE

NitroMist™ (nitroglycerin lingual aerosol) was approved by the U.S. Food & Drug Administration (FDA) in November 2006 for acute relief of an attack or acute prophylaxis of angina pectoris due to coronary artery disease.

Zensana™ (ondansetron HCl) oral spray contains the most widely prescribed anti-emetic compound, ondansetron. It has the potential to be a more convenient alternative to the tablet, intravenous and suppository forms of the drug, which are marketed by GlaxoSmithKline under the brand name Zofran®.

Zolpidem Oral Spray uses NovaDel's proprietary formulation technology to deliver zolpidem tartrate, which is currently marketed in oral form by Sanofi-Aventis as Ambien® for the treatment of insomnia.

Sumatriptan Oral Spray is NovaDel's proprietary oral spray formulation of sumatriptan being developed for the potential treatment of migraine headaches. Sumatriptan is the active

ingredient in GlaxoSmithKline's Imitrex®, the leading prescription therapy for migraines in the U.S., which is available as a tablet and in injectable and intranasal formulations.

Tizanidine Oral Spray is being developed by NovaDel as potential treatment for spasticity. Tizanidine is the active ingredient in Acorda Therapeutics' marketed product Zanaflex®. The drug, currently only available as an oral tablet and capsule, works by blocking nerve impulses through pre-synaptic inhibition of motor neurons, resulting in decreased spasticity without reduction in muscle strength.

Ropinirole Oral Spray is being developed as a potential treatment for Parkinson's Disease. Ropinirole is the active ingredient in Requip®, which is indicated for the treatment of the signs and symptoms of idiopathic Parkinson's disease, a neurological movement disorder characterized by sensory and motor abnormalities. Requip® is marketed by GlaxoSmithKline.

Company Description

NovaDel Pharma Inc. is a specialty pharmaceutical company developing oral spray formulations of a broad range of marketed therapeutics. The Company's proprietary technology enables rapid delivery of drugs into the bloodstream, which results in faster onset of action and potential patient benefits in compliance, convenience and safety. NovaDel's most advanced candidates target nausea, insomnia, migraine headaches and disorders of the central nervous system (CNS).